Cellumen’s cardiac hypertrophy panel is designed to simultaneously measure eight distinct toxicity indicators in drug compounds including mitochondrial function, oxidative stress, apoptosis, and cellular hypertrophy.
By leveraging Cellumen’s discovery toxicology approach, the panel quantifies both the mechanism and time course of toxicity. In addition, the proprietary CellCiphr Classifier, an integral component of the panel, provides a quick, objective means to identify compounds that may cause cardiac-specific toxicity, the company said.
According to the company, by integrating this new panel into its CellCiphr discovery toxicology profiling services, drug companies can now save millions of dollars in development costs that are typically wasted by not identifying toxic compounds earlier.
Lansing Taylor, CEO of Cellumen, said: “The CellCiphr cardiac hypertrophy panel is the next step in helping the FDA realize their goal to first minimize and then to replace animal testing within the next 10 years.”